Skip to main content
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Oct 1;5(4):548–557. doi: 10.1016/j.nurt.2008.08.008

Idiopathic inflammatory myopathies: Current and future therapeutic options

Heinz Wiendl 1,
PMCID: PMC4514694  PMID: 19019306

Summary

Idiopathic inflammatory myopathies (notably polymyositis and dermatomyositis) are relatively uncommon diseases with a heterogeneous clinical presentation. Only a few randomized, double-blind, placebo-controlled trials have been performed, measures to assess outcome and response to treatment have to be validated. Initial treatment options of first choice are corticosteroids, although rarely tested in randomized, controlled trials. Unfortunately, not all patients respond to them and many develop undesirable side effects. Thus, second line agents or immunosuppressants given in combination with corticosteroids are used. For dermatomyositis/polymyositis, combination with azathioprine is most common. In case this combination is not sufficient or applicable, intravenous immunoglobulins are justified. Alternative or stronger immunosuppressants, such as cyclosporine A, cyclophosphamide, methotrexate, or mycophenolate are also used. There are no defined guidelines or best treatment protocols agreed on internationally; therefore, the medical approach must be individualized based on the severity of clinical presentation, disease duration, presence of extramuscular features, and prior therapy and contraindications to particular agents. Approximately 25% of patients are non-responders and continue to experience clinical relapses. Those are candidates for alternative treatment options and experimental therapies.

New immunoselective therapies directed toward cytokine modulation, immune cell migration, or modification of certain immune subsets (B- and T-cells) are a promising avenue of research and clinical application. Possible future therapeutic options are presented and discussed.

Key Words: Idiopathic inflammatory myopathies, myositis, therapy, polymyositis, dermatomyositis, inclusion body myositis

References

  • 1.Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: Mc Graw Hill; 1994. pp. 1335–1383. [Google Scholar]
  • 2.Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–982. doi: 10.1016/S0140-6736(03)14368-1. [DOI] [PubMed] [Google Scholar]
  • 3.Goebels N, Pongratz D. Myositiden. In: Brandt Th, Dichgans J, Diener HC., editors. Therapie und Verlauf neurologischer Erkrankungen. 4th ed. Stuttgart: Kohlhammer Verlag; 2003. pp. 1284–1299. [Google Scholar]
  • 4.Amato AA, Griggs RC. Treatment of inflammatory myopathies. Curr Opin Neurol. 2003;16:569–575. doi: 10.1097/00019052-200310000-00002. [DOI] [PubMed] [Google Scholar]
  • 5.Hengstman GJ, van Engelen BG. Polymyositis: an overdiagnosed entity. Neurology. 2004;63:402–3. doi: 10.1212/WNL.63.2.402. [DOI] [PubMed] [Google Scholar]
  • 6.Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 2005;26:373–380. doi: 10.1016/j.it.2005.05.003. [DOI] [PubMed] [Google Scholar]
  • 7.Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2:398–398. doi: 10.1038/ncprheum0220. [DOI] [PubMed] [Google Scholar]
  • 8.Hohlfeld R, Dornmair K. Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology. 2007;69:1966–1967. doi: 10.1212/01.wnl.0000279589.06059.37. [DOI] [PubMed] [Google Scholar]
  • 9.Chevrel G, Goebels N, Hohlfeld R. Myositis: Diagnosis and management. Pract Neurol. 2002;1:4–11. doi: 10.1046/j.1474-7766.2002.00302.x. [DOI] [Google Scholar]
  • 10.Hohlfeld R. Polymyositis and Dermatomyositis. In: Karpati G, editor. Structural and molecular basis of skeletal muscle disease. Basel: ISN Neuropath Press; 2002. pp. 221–227. [Google Scholar]
  • 11.Wiendl H, Hohlfeld R, Kieseier BC. Muscle-derived positive and negative regulators of the immune response. Curr Opin Rheumatol. 2005;17:714–719. doi: 10.1097/01.bor.0000184164.69181.ca. [DOI] [PubMed] [Google Scholar]
  • 12.Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol. 2008;4:201–209. doi: 10.1038/ncprheum0760. [DOI] [PubMed] [Google Scholar]
  • 13.Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6:620–631. doi: 10.1016/S1474-4422(07)70171-0. [DOI] [PubMed] [Google Scholar]
  • 14.Dalakas MC. Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2:437–447. doi: 10.1038/ncpneuro0261. [DOI] [PubMed] [Google Scholar]
  • 15.Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol. 2007;19:550–559. doi: 10.1097/BOR.0b013e3282efdc7c. [DOI] [PubMed] [Google Scholar]
  • 16.Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006;25:231–239. doi: 10.1007/s10067-005-1164-z. [DOI] [PubMed] [Google Scholar]
  • 17.Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H. Polymyositis and dematomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol. 2002;28:2230–2237. [PubMed] [Google Scholar]
  • 18.Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002;41:7–13. doi: 10.1093/rheumatology/41.1.7. [DOI] [PubMed] [Google Scholar]
  • 19.Miller FW, Rider LG, Chung YL, et al. International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262–1273. doi: 10.1093/rheumatology/40.11.1262. [DOI] [PubMed] [Google Scholar]
  • 20.Isenberg DA, Allen E, Farewell V, et al. International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43:49–54. doi: 10.1093/rheumatology/keg427. [DOI] [PubMed] [Google Scholar]
  • 21.Bunch TW. Prednisone and azathioprine for polymyositis: longterm follow-up. Arthritis Rheum. 1981;24:45–48. doi: 10.1002/art.1780240107. [DOI] [PubMed] [Google Scholar]
  • 22.Riley SA, Williams SE, Cooke NJ. Alveolitis after treatment with amiodarone. Br Med J (Clin Res Ed) 1982;284(6310):161–162. doi: 10.1136/bmj.284.6310.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2005;7:99–105. doi: 10.1007/s11926-005-0061-4. [DOI] [PubMed] [Google Scholar]
  • 24.Fossaluzza V, De Vita S. Clinical differences between ANA/anti-ENA positive or negative primary Sjögren’s syndrome. Clin Rheumatol. 1992;11:385–387. doi: 10.1007/BF02207198. [DOI] [PubMed] [Google Scholar]
  • 25.Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005;44:386–389. doi: 10.1093/rheumatology/keh499. [DOI] [PubMed] [Google Scholar]
  • 26.Choudry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94–96. doi: 10.1212/WNL.56.1.94. [DOI] [PubMed] [Google Scholar]
  • 27.Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006;34:284–291. doi: 10.1002/mus.20543. [DOI] [PubMed] [Google Scholar]
  • 28.Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65:639–641. doi: 10.1212/01.wnl.0000173031.56429.04. [DOI] [PubMed] [Google Scholar]
  • 29.Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermato-myositis. N Engl J Med. 1994;329:1993–2000. doi: 10.1056/NEJM199312303292704. [DOI] [PubMed] [Google Scholar]
  • 30.Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006;18:503–506. doi: 10.1097/01.bor.0000240362.32089.4c. [DOI] [PubMed] [Google Scholar]
  • 31.Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheumat. 2002;46:467–474. doi: 10.1002/art.10053. [DOI] [PubMed] [Google Scholar]
  • 32.Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–2375. doi: 10.1001/jama.291.19.2367. [DOI] [PubMed] [Google Scholar]
  • 33.Mastaglia FL, Zilko PJ. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci. 2003;10:99–101. doi: 10.1016/S0967-5868(02)00271-0. [DOI] [PubMed] [Google Scholar]
  • 34.Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology. 1997;48:863–866. doi: 10.1212/WNL.48.4.863. [DOI] [PubMed] [Google Scholar]
  • 35.Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–327. doi: 10.1212/WNL.56.3.323. [DOI] [PubMed] [Google Scholar]
  • 36.Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61:260–262. doi: 10.1212/01.WNL.0000071852.27182.C7. [DOI] [PubMed] [Google Scholar]
  • 37.Nakayama T, Horiuchi E, Watanabe T, Murayama S, Nakase H. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption. J Neurol Neurosurg Psychiatry. 2000;68:230–233. doi: 10.1136/jnnp.68.2.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58:1081–1087. doi: 10.1212/WNL.58.7.1081. [DOI] [PubMed] [Google Scholar]
  • 39.Dalakas MC, Rakocevic G, McElroy B, Salajegheh M, Love MH, Shrader J, Levy E, Kirk AD. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM): a treatment trial in patients with established natural history data. AAN 2007, S57.001. Neurology. 2007;12(suppl 168):A361–A361. [Google Scholar]
  • 40.Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology. 1997;48:712–716. doi: 10.1212/WNL.48.3.712. [DOI] [PubMed] [Google Scholar]
  • 41.Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22–28. doi: 10.1007/s004150050005. [DOI] [PubMed] [Google Scholar]
  • 42.Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D’Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007;46:516–518. doi: 10.1093/rheumatology/kel336. [DOI] [PubMed] [Google Scholar]
  • 43.Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245–1247. doi: 10.1212/01.wnl.0000208416.32471.c0. [DOI] [PubMed] [Google Scholar]
  • 44.Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(suppl 1):S123–124. doi: 10.1212/01.wnl.0000192258.32408.54. [DOI] [PubMed] [Google Scholar]
  • 45.Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–2446. doi: 10.1002/art.21240. [DOI] [PubMed] [Google Scholar]
  • 46.Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38:383–392. doi: 10.1080/08916930500124023. [DOI] [PubMed] [Google Scholar]
  • 47.Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23:707–710. [PubMed] [Google Scholar]
  • 48.Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008–2019. doi: 10.1212/01.WNL.0000291619.17160.b8. [DOI] [PubMed] [Google Scholar]
  • 49.Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56:3107–3111. doi: 10.1002/art.22856. [DOI] [PubMed] [Google Scholar]
  • 50.Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763–767. doi: 10.1001/archderm.143.6.763. [DOI] [PubMed] [Google Scholar]
  • 51.Dinh HV, McCormack C, Hall S, et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56:148–153. doi: 10.1016/j.jaad.2006.05.068. [DOI] [PubMed] [Google Scholar]
  • 52.Ferrer E, Moral MA. Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura. Drug News Perspect. 2006;19:482–484. doi: 10.1358/dnp.2006.19.3.985929. [DOI] [PubMed] [Google Scholar]
  • 53.Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65:974–975. doi: 10.1136/ard.2005.045898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264–266. doi: 10.1097/01.rhu.0000182155.08982.60. [DOI] [PubMed] [Google Scholar]
  • 55.Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369–1370. [PubMed] [Google Scholar]
  • 56.Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601–607. doi: 10.1002/art.20849. [DOI] [PubMed] [Google Scholar]
  • 57.Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33:1021–1026. [PubMed] [Google Scholar]
  • 58.Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label pilot study. Ann Rheum Dis. 2007;66(suppl II):216–216. [Google Scholar]
  • 59.Lebwohl M, Tyring SK, Hamilton TK, Efalizumab Study Group et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013. doi: 10.1056/NEJMoa030002. [DOI] [PubMed] [Google Scholar]
  • 60.Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, Alexander DR. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol. 2003;33:666–675. doi: 10.1002/eji.200323586. [DOI] [PubMed] [Google Scholar]
  • 61.Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006;24:233–238. doi: 10.1016/j.immuni.2006.03.001. [DOI] [PubMed] [Google Scholar]
  • 62.Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004;113:38–46. doi: 10.1016/j.clim.2004.06.001. [DOI] [PubMed] [Google Scholar]
  • 63.Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Proc Natl Acad Sci USA. 2005;102:19057–19062. doi: 10.1073/pnas.0509736102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49:S98–104. doi: 10.1016/S0190-9622(03)01141-1. [DOI] [PubMed] [Google Scholar]
  • 65.Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664–678. doi: 10.1002/ana.20464. [DOI] [PubMed] [Google Scholar]
  • 66.Schmidt KN, Ouyang W. Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. Lupus. 2004;13:348–352. doi: 10.1191/0961203304lu1025oa. [DOI] [PubMed] [Google Scholar]
  • 67.Stewart TA. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 2003;14:139–154. doi: 10.1016/S1359-6101(02)00088-6. [DOI] [PubMed] [Google Scholar]
  • 68.Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med. 2001;194:1823–1834. doi: 10.1084/jem.194.12.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Patole PS, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, Anders HJ. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol. 2005;16:3273–3280. doi: 10.1681/ASN.2005060658. [DOI] [PubMed] [Google Scholar]
  • 70.Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008;4:384–398. doi: 10.1038/ncpneuro0832. [DOI] [PubMed] [Google Scholar]
  • 71.Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, Amato AA. Molecular profiles of inflammatory myopathies. Neurology. 2002;59(8):1170–1182. doi: 10.1212/WNL.59.8.1170. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES